Fludarabine-based chemotherapy in untreated mantle cell lymphomas: An encouraging experience in 29 patients

Haematologica

Volumn 84, Issue 11, 1999, Pages 1002-1006

  Zinzani, Pier Luigi ^a   Magagnoli, Massimo ^b   Moretti, Luciano ^b   Battista, Raffaele ^b   Ronconi, Fioravante ^b   De Renzo, Amalia ^b   Zaccaria, Alfonso ^b   Gentilini, Patrizia ^b   Guardigni, Luciano ^b   Gherlinzoni, Filippo ^b   Cellini, Claudia ^b   Fattori, Pier Paolo ^b   Bendandi, Maurizio ^b   Bocchia, Monica ^b   Aitini, Enrico ^b   Tura, Sante ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

Complete response; Fludarabine; Fludarabine in combination; Idarubicin; Mantle cell lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; IDARUBICIN; MITOXANTRONE;

ADULT; AGED; ARTICLE; CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MANTLE CELL LYMPHOMA; NEUTROPENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; AGRANULOCYTOSIS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IDARUBICIN; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; VIDARABINE;

EID: 0032758414     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic and molecular data. Am J Surg Pathol 1992; 16:637-40.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American Classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-92.
3. Zucca E, Stein H, Coiffier B. European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL). Ann Oncol 1994; 5:507-11.
4. Weisenburger DD, Armitage JO. Mantle Cell Lymphoma: an entity comes of age. Blood 1996; 87:4483-94.
5. Lardelli P, Bookman MA, Sundeen J, et al. Lymphocytic lymphoma of intermediate differentiation: morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol 1990; 14:752-63.
6. Berger F, Felman P, Sonat A, et al. Nonfollicular small B-cell lymphomas: a heterogenous group of patients with distinct clinical features and outcome. Blood 1994; 83:2829-35.
7. Meusers P, Engelhard M, Bartels H, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989; 7:365-80.
8. Bertini M, Rus C, Freilone R, et al. Mantle cell lymphoma: a retrospective study on 27 patients. Clinical features and natural history. Haematologica 1998; 83:312-6.
9. Zucca E, Roggero E, Pinotti G, et al. Pattern of survival in mantle cell lymphomas. Ann Oncol 1995; 6:257-62.
10. Redman JR, Cabanillas F, Velasques WS, et al. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 1992; 109:790-4.
11. Hochster HS, Kim K, Green MD, et al. Activity of fludarabine in previously treated non-Hodgkin's lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992; 10:28-32.
12. Zinzani PL, Lauria F, Rondelli D, et al. Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 1993; 4:575-8.
13. Hiddeman W, Unterhalt M, Pott C, et al. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: A phase II study of the German low-grade non-Hodgkin's lymphoma study group. Semin Oncol 1993; 20:28-31.
14. Pigaditou A, Rohatiner AZS, Whelan JS, et al. Fludarabine in low-grade lymphoma. Semin Oncol 1993; 20:24-7.
15. Solal-Cèligny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996; 14:514-9.
16. McLaughlin P, Hagemeister FB, Swan F, et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 1994; 12:575-9.
17. Pott C, Unterhalt M, Sandford D, et al. Fludarabine as single agent and in combination with mitoxantrone and dexamethasone in relapsed and refractory low-grade non-Hodgkin's lymphoma. Ann Haematol 1994; 68 (Suppl. 1):A3.
18. Zinzani PL, Bendandi M, Tura S. FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma. Eur J Haematol 1995; 55:262-6.
19. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14:1262-8.
20. Zinzani PL, Bendandi M, Magagnoli M, et al. Fludarabine mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann Oncol 1997; 8:379-83.
21. Zinzani PL, Bendandi M, Gherlinzoni F, et al. FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non Hodgkin's lymphoma. Haematologica 1996; 81:168-71.
22. Hochster H, Oken M, Bennet J, et al. Efficacy of cyclophosphamide (CYC) and fludarabine (FAMP) as first line therapy of low-grade non Hodgkin's lymphoma (NHL)-ECOG 1491. Blood 1994; 84(Suppl 1):383a.
23. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31:1860-1.
24. Shipp M, Harrington D, Anderson J, et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329:987-94.
25. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-81.
26. Oken M, Creech R, Tormey D. Toxocity and response criteria of the Eastern Cooperative Oncology Group. Am J Clinic Oncol 1982; 5:649-55.
27. Keating MJ, McLaughlin P, Cabanillas F. Low-grade non-Hodgkin's lymphoma - a development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND). Eur J Cancer Care 1997; 6:21-6.
28. Zinzani PL. Idarubicin in low-grade non-Hodgkin's lymphomas. Haematologica 1997; 82 (Suppl to n.5): 23-4.
29. Decaudin D, Bosq J, Tertian G, et al. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 1998; 16:579-83.
30. Montserrat E, Perales M, Cobo F, et al. Fludarabine, cyclophosphamide and mitoxantrone (FCM) in resistant or relapsed chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL). Ann Hematol 1998; 77 (Suppl 1):A6.
31. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92:1927-32.
32. Arguello F, Alexander M, Sterry JA, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998; 91:2482-90.